Impact of somatostatin receptor scintigraphy in patients with suspected meningeoma

To evaluate the usefulness of somatostatin receptor scintigraphy (SRS) in patients with suspected meningeoma, 58 patients were investigated prior to surgery receiving standard MRI and SRS following i.v. injection of 200 MBq In-111-octreotide. SRS was true positive in 44/58, true negative in 5 neurinoma, and false negative in 9 patients. In the latter tumor volume was < 10 ml. MRI was decisive for meningeoma in 39/58 patients. In 14/58 patients MRI could not differentiate between meningeoma and neurinoma. Of these, positive SRS confirmed meningeoma in 9 patients, and negative SRS excluded meningeoma in the remaining 5. In conclusion, SRS has significant clinical impact in patients with suspected meningeoma following MRI.